About this trial
While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.
Eligibility criteria
Qualifiers
Age 18 - 65 years old
BMI 19-30 kg/m2
English fluency
Disqualifiers
Individuals with current moderate or severe substance use disorder, no past stimulant or cocaine use disorder
Individuals with current acute or high risk of suicide or suicide attempt in past 6 months
Individuals with current psychotic or bipolar disorder
Individuals with past schizophrenia, schizoaffective disorder, psychotic bipolar disorder, stimulant or cocaine use disorder
Trial design
Treatments tested in this trial
- Placebo
- Adderall
Treatment groups
Locations
1Sponsors and collaborators
University of Chicago
Lead sponsor
Cures Within Reach
Collaborator